Boehringer Ingelheim

News

Boehringer licenses Sosei schizophrenia drugs in €755m deal

Boehringer Ingelheim has taken an option on a family of compounds with potential as therapies for schizophrenia from Sosei Heptares, which it says could have broad activit

News

Boehringer’s survodutide shows monster MASH potential

Boehringer Ingelheim’s weight-loss drug candidate survodutide could also be effective for liver disease metabolic dysfunction-associated steatohepatitis (MASH), if the res

R&D

This week in clinical trials: 8th-12th January

In our second clinical trials update of 2024, taking in developments in life sciences research and development from early-stage onwards, we look at a wide range of announcements – from onco

News

Click bags FDA breakthrough tag for schizophrenia DTx

Digital health company Click Therapeutics has won an FDA breakthrough device designation for CT-155, a digital therapeutic (DTx) for the negative symptoms of schizophrenia

News

Boehringer targets NASH/MASH with $2bn Ribo alliance

Boehringer Ingelheim has signed a multi-target collaboration with China’s Suzhou Ribo Life Science and its Swedish unit Ribocure to develop treatments for non-alcoholic or

News

FDA starts speedy review of Amgen’s lung cancer BiTE therapy

The FDA has started a priority review of Amgen’s tarlatamab for small cell lung cancer (SCLC), the lead drug in the company’s pipeline of bispecific T-cell engager (BiTE)

Boehringer licenses Sosei schizophrenia drugs in €755m deal

Boehringer’s survodutide shows monster MASH potential

This week in clinical trials: 8th-12th January

Click bags FDA breakthrough tag for schizophrenia DTx

Boehringer targets NASH/MASH with $2bn Ribo alliance

FDA starts speedy review of Amgen’s lung cancer BiTE therapy

On the future of AI in life sciences, with women at the helm

How to meet your physicians where they are online

Boehringer Ingelheim

Editor's Picks